Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report : International Clinical Psychopharmacology

Secondary Logo

Journal Logo

Advanced Search
Case Reports

Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report

Ricci, Valerioa; Di Salvo, Gabrieleb; Maina, Giuseppeb

Author Information

aDepartment of Psychiatry, San Luigi Gonzaga University Hospital, Regione Gonzole, Orbassano

bRita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy

Received 13 December 2022 Accepted 6 February 2023.

Correspondence to Valerio Ricci, MD, PhD, Department of Psychiatry, San Luigi Gonzaga University Hospital, Regione Gonzole, 10, Orbassano, Turin 10043, Italy, Tel: +39 3929659725; e-mail: [email protected]

International Clinical Psychopharmacology 38(4):p 275-280, July 2023. | DOI: 10.1097/YIC.0000000000000465

Abstract

Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have an antidepressant effect due to 5-HT7 as well as 5-HT2A and 5-HT1a receptor affinity. Here we present a case of a 19-year-old male patient with first-episode psychosis (FEP) and predominant depressive symptoms. Remarkable clinical and functional improvement was observed 3 months after the beginning of lurasidone treatment. The patient’s depressive symptoms disappear with a dramatic reduction of psychotic ones, with good tolerance of the drug and without adverse effects. Lurasidone seems to be a promising treatment option for FEP with predominant depressive symptoms.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid